Janux Therapeutics advances prostate cancer treatment as stock soars
Janux Therapeutics made headlines with an extraordinary 54% surge in after-hours trading on Monday, bringing its stock price to $61.79. This sharp rise followed the ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
Zynext Ventures invests in Promaxo’s innovative MRI and robotic technologies
Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has made a significant investment in Promaxo Inc., a leading developer of portable low-field ... Read More
Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in ... Read More